Close
4

Quotient Sciences Quotient Sciences

X

Company profile for Immodulon Therapeutics

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. IMM-101 has a unique mechanism of action that should not only make this innovative product applicable to a large range of cance...
Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. IMM-101 has a unique mechanism of action that should not only make this innovative product applicable to a large range of cancers but, in combination with immune checkpoint inhibitors and other standard-of-care treatments, is expected to enhance their efficacy without increasing the safety burden for the patient.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Immodulon Therapeutics
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
6-9 The Square Stockley Park Uxbridge UB11 1FW
Telephone
Telephone
+44 (0) 20 3137 6346
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY